Schwabe D, Sahm S, Gerein V, Happ J, Kropp-von Rabenau H, Maul F, Baum R P, Manegold K, Nitz C, Hör G
Eur J Pediatr. 1987 May;146(3):246-50. doi: 10.1007/BF00716467.
Eleven children with neuroblastoma refractory to conventional therapy or relapse of neuroblastoma were treated with 131-metaiodobenzylguanedine (MIBG). The therapeutic results and the side effects were evaluated. In one patient with disseminated bone marrow involvement complete remission was obtained. Partial remission was observed in six patients and stable disease in another. Three patients did not respond to MIBG, in two of them the tumours did not accumulate a sufficient MIBG dose. Clinical and laboratory examinations revealed an excellent tolerance of MIBG in all patients. First attempts to continue cytostasis after MIBG therapy were made. MIBG has a good therapeutic efficacy is sufficiently incorporated into the tumour cell.
11例对常规治疗难治或复发的神经母细胞瘤患儿接受了131-间碘苄胍（MIBG）治疗。对治疗结果和副作用进行了评估。1例有弥漫性骨髓受累的患者获得完全缓解。6例患者观察到部分缓解，另1例病情稳定。3例患者对MIBG无反应，其中2例肿瘤未积累足够的MIBG剂量。临床和实验室检查显示所有患者对MIBG耐受性良好。首次尝试在MIBG治疗后继续进行细胞抑制治疗。MIBG具有良好的治疗效果，能充分掺入肿瘤细胞。
